Compare Medpace Holdings Inc (MEDP) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Thomson Reuters Corp — how do they compare? Medpace Holdings Inc trades at $534.38 (market cap $15.08B), while Thomson Reuters Corp trades at $91.29 (market cap $41.28B). The key difference: Thomson Reuters Corp is far larger — about 2.7× Medpace Holdings Inc's market cap, and Thomson Reuters Corp pays a 2.75% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TRI | |
|---|---|---|
Market Cap | $15.08B | $41.28B |
Sector | Technology | Industrials |
52-Week High | $620.59 | $205.54 |
52-Week Low | $308.88 | $76.55 |
Enterprise Value | $14.55B | $43.24B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Thomson Reuters (TRI) trades at $95.43, down 0.8% today, with a bullish technical signal and strong analyst consensus. The stock shows robust profitability with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent corporate actions include a special dividend and a reverse stock split, while news highlights AI integration and a joint venture with KKR.
Outlook is positive with a consensus price target of $129.96 implying 36% upside, supported by solid cash flow and debt reduction. Risks include execution of AI strategy and competitive pressures. Wall Street sentiment is bullish with 52% buy ratings, but investors should monitor Q2 2026 earnings due August 5 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
